Okigbo Adaora A, Helkowski Michael S, Royes Brittany J, Bleimeister Isabel H, Lam Tracey R, Bao Gina C, Cheng Jeffrey P, Bondi Corina O, Kline Anthony E
Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA, 15213, United States; Safar Center for Resuscitation Research, University of Pittsburgh, Pittsburgh, PA, 15213, United States.
Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA, 15213, United States; Safar Center for Resuscitation Research, University of Pittsburgh, Pittsburgh, PA, 15213, United States; Neurobiology, University of Pittsburgh, Pittsburgh, PA, 15213, United States; Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA, 15213, United States.
Neurosci Lett. 2019 Feb 16;694:69-73. doi: 10.1016/j.neulet.2018.11.030. Epub 2018 Nov 22.
Numerous pharmacotherapies have been evaluated after experimental traumatic brain injury (TBI). While amantadine (AMT) has shown potential for clinical efficacy, the few studies on its effectiveness have been mixed. It is possible that suboptimal dosing, due to the evaluation of only one dose, may be causing the discrepancies in outcomes. Hence, the goal of the current study was to conduct a dose response of AMT after TBI to determine an optimal behavioral benefit. Anesthetized adult male rats received either a cortical impact of moderate severity or sham injury and then were randomly assigned to receive once daily intraperitoneally injections of AMT (10, 20, or 40 mg/kg) or saline vehicle (VEH, 1 mL/kg) commencing 24 h after injury for 19 days. Motor and cognitive function were assessed on post-operative days 1-5 and 14-19, respectively. There were no statistical differences among the sham groups treated with AMT or VEH so the data were pooled. AMT (20 mg/kg) facilitated beam-balance recovery and spatial learning relative to VEH-treated controls (p < 0.05). No other doses of AMT were effective. These results indicate that dosing should be carefully considered when assessing the effects of pharmacotherapies after TBI so that potential benefits are not inadvertently missed.
在实验性创伤性脑损伤(TBI)后,已经对多种药物疗法进行了评估。虽然金刚烷胺(AMT)已显示出临床疗效的潜力,但关于其有效性的少数研究结果却参差不齐。由于仅评估了一种剂量,可能是次优剂量导致了结果的差异。因此,本研究的目的是在TBI后进行AMT的剂量反应研究,以确定最佳行为益处。将成年雄性大鼠麻醉后,给予中度严重程度的皮质撞击或假手术损伤,然后在损伤后24小时开始,随机分配接受每日一次腹腔注射AMT(10、20或40mg/kg)或生理盐水载体(VEH,1mL/kg),持续19天。分别在术后第1-5天和第14-19天评估运动和认知功能。接受AMT或VEH治疗的假手术组之间没有统计学差异,因此将数据合并。与接受VEH治疗的对照组相比,AMT(20mg/kg)促进了平衡木恢复和空间学习(p<0.05)。其他剂量的AMT均无效。这些结果表明,在评估TBI后药物疗法的效果时,应仔细考虑剂量,以免无意中错过潜在益处。